ITeos Therapeutics To Wind Down Clinical And Operational Activities, Stock Up In Pre-Market

(RTTNews) - Biopharmaceutical company iTeos Therapeutics, Inc. (ITOS), Wednesday announced its decision to wind down its clinical and operational activities to focus on maximizing shareholder value.

The decision is a part of a comprehensive review into the company's development pipeline, business prospects, and financial position.

Additionally, the company is exploring the potential sale of its intellectual property and assets such as EOS-984, EOS-215, and a pre-clinical obesity program targeting ENT1 to deliver near-term value to shareholders.

In the pre-market hours, ITOS is climbing 24.97 percent, to $10.66 on the Nasdaq.